These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 33151783)

  • 21. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
    Tan PT; Aziz MIA; Pearce F; Lim WT; Wu DB; Ng K
    BMC Cancer; 2018 Mar; 18(1):352. PubMed ID: 29587666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.
    Planchard D; Boyer MJ; Lee JS; Dechaphunkul A; Cheema PK; Takahashi T; Gray JE; Tiseo M; Ramalingam SS; Todd A; McKeown A; Rukazenkov Y; Ohe Y
    Clin Cancer Res; 2019 Apr; 25(7):2058-2063. PubMed ID: 30659024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer.
    Lemmon CA; Zabor EC; Pennell NA
    Oncologist; 2022 May; 27(5):407-413. PubMed ID: 35285487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (
    Nilsson FOL; Gal P; Houisse I; Ivanova JI; Asanin ST
    J Med Econ; 2021; 24(1):447-457. PubMed ID: 33754924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
    Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
    Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.
    Lim EA; Lee H; Bae E; Lim J; Shin YK; Choi SE
    PLoS One; 2016; 11(8):e0160155. PubMed ID: 27483001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in
    Girard N; Moro-Sibilot D; Bouée S; Emery C; Torreton E; Le Lay K; Luciani L; Maritaz C; Chouaid C
    Future Oncol; 2020 Jun; 16(16):1115-1124. PubMed ID: 32352321
    [No Abstract]   [Full Text] [Related]  

  • 28. Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.
    Zhu J; Li T; Wang X; Ye M; Cai J; Xu Y; Wu B
    BMC Cancer; 2013 Jan; 13():39. PubMed ID: 23360224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand.
    Limwattananon C; Limwattananon S; Waleekhachonloet O; Rattanachotphanit T
    Lung Cancer; 2018 Jun; 120():91-97. PubMed ID: 29748023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.
    Vergnenegre A; Massuti B; de Marinis F; Carcereny E; Felip E; Do P; Sanchez JM; Paz-Arez L; Chouaid C; Rosell R;
    J Thorac Oncol; 2016 Jun; 11(6):801-7. PubMed ID: 26899757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations.
    Westerink L; Nicolai JLJ; Samuelsen C; Smit HJM; Postmus PE; Griebsch I; Postma MJ
    Eur J Health Econ; 2020 Aug; 21(6):931-943. PubMed ID: 32328874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
    Narita Y; Matsushima Y; Shiroiwa T; Chiba K; Nakanishi Y; Kurokawa T; Urushihara H
    Lung Cancer; 2015 Oct; 90(1):71-7. PubMed ID: 26259876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Gu X; Zhang Q; Chu YB; Zhao YY; Zhang YJ; Kuo D; Su B; Wu B
    Lung Cancer; 2019 Jan; 127():84-89. PubMed ID: 30642557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
    Rangachari D; To C; Shpilsky JE; VanderLaan PA; Kobayashi SS; Mushajiang M; Lau CJ; Paweletz CP; Oxnard GR; Jänne PA; Costa DB
    J Thorac Oncol; 2019 Nov; 14(11):1995-2002. PubMed ID: 31377341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
    Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
    Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overall Survival with Osimertinib in Untreated,
    Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
    N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
    Huang YH; Tseng JS; Hsu KH; Chen KC; Su KY; Yu SL; Chen JJW; Yang TY; Chang GC
    Sci Rep; 2021 Jun; 11(1):12084. PubMed ID: 34103652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study.
    Cheng Y; He Y; Li W; Zhang HL; Zhou Q; Wang B; Liu C; Walding A; Saggese M; Huang X; Fan M; Wang J; Ramalingam SS
    Target Oncol; 2021 Mar; 16(2):165-176. PubMed ID: 33544337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China.
    Shu Y; Ding Y; He X; Liu Y; Wu P; Zhang Q
    Front Pharmacol; 2022; 13():920479. PubMed ID: 36204237
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.